Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. Objective: The objective of this study was to investigate the changes of laboratory values and related risk factors in patients with psoriasis treated with CsA in a real-world setting. Methods: Records of patients with psoriasis treated with CsA at an outpatient clinic were collected, and a Cox proportional hazards regression model was used. Results: Of the 128 patients included in this study, 28 patients (21.9%) showed laboratory test abnormalities over a mean medication period of 11.6 months. Older age (hazard ratio [HR], 1.174; 95% confidence interval [CI], 1.068∼1.370; p=0.007) and pre-existing kidney disease (HR, 0.008; 95% CI, 0∼ 0.205; p=0.001) significantly increased the risk of renal dysfunction. Male sex was the only significant risk factor for liver enzyme elevation (HR, 0.284; 95% CI, 0.081∼0.784; p=0.026) and uric acid abnormality (HR, 0.048; 95% CI, 0∼ 0.372; p=0.046). Conclusion: This is an in-depth analysis of laboratory changes and related risk factors in patients with psoriasis treated with CsA. Liver is the most commonly affected organ of CsA toxicity. Older age, male sex, and presence of kidney disease were risk factors associated with laboratory abnormality during CsA treatment.
Abstract
Background: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. Objective: The objective of this study was to investigate the changes of laboratory values and related risk factors in patients with psoriasis treated with CsA in a real-world setting. Methods: Records of patients with psoriasis treated with CsA at an outpatient clinic were collected, and a Cox proportional hazards regression model was used. Results: Of the 128 patients included in this study, 28 patients (21.9%) showed laboratory test abnormalities over a mean medication period of 11.6 months. Older age (hazard ratio [HR], 1.174; 95% confidence interval [CI], 1.068∼1.370; p=0.007) and pre-existing kidney disease (HR, 0.008; 95% CI, 0∼ 0.205; p=0.001) significantly increased the risk of renal dysfunction. Male sex was the only significant risk factor for liver enzyme elevation (HR, 0.284; 95% CI, 0.081∼0.784; p=0.026) and uric acid abnormality (HR, 0.048; 95% CI, 0∼ 0.372; p=0.046). Conclusion: This is an in-depth analysis of laboratory changes and related risk factors in patients with psoriasis treated with CsA. Liver is the most commonly affected organ of CsA toxicity. Older age, male sex, and presence of kidney disease were risk factors associated with laboratory abnormality during CsA treatment.
참고문헌 (16)
- Griffiths CE, "A systematic review of treatments for severe psoriasis", Health Technol Assess, 4, pp.1~125 (2000)
- Amor KT, "The use of cyclosporine in dermatology: part I", J Am Acad Dermatol, 63, pp.925~946 (2010)[DOI]
- Markham T, "Adverse effects with long-term cyclosporin for severe psoriasis", Clin Exp Dermatol, 27, pp.111~114 (2002)[DOI]
- Garcia-Bustinduy M, "Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series", J Eur Acad Dermatol Venereol, 18, pp.169~172 (2004)[DOI]
- Lebwohl M, "Cyclosporine consensus conference: with emphasis on the treatment of psoriasis", J Am Acad Dermatol, 39, pp.464~475 (1998)[DOI]
- Grossman RM, "Long-term safety of cyclosporine in the treatment of psoriasis", Arch Dermatol, 132, pp.623~629 (1996)[DOI]
- Rosmarin DM, "Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference", J Am Acad Dermatol, 62, pp.838~853 (2010)[DOI]
- Griffiths CE, "Ciclosporin in psoriasis clinical practice: an international consensus statement", Br J Dermatol, 150(Suppl 67), pp.11~23 (2004)
- Berth-Jones J, "The use of ciclosporin in psoriasis", J Dermatolog Treat, 16, pp.258~277 (2005)[DOI]
- Colombo MD, "Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches", ScientificWorldJournal, 2013, pp.805705~ (2013)
- Yoon HS, "A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis", J Dermatolog Treat, 18, pp.286~290 (2007)[DOI]
- 김상엽, "중등증 내지 중증 판상건선에서 Methotrexate와Cyclosporine A의 효능 및 부작용에 대한 비교", 대한피부과학회지, 52(9), pp.615~621 (2014), 대한피부과학회
- 김민주, "만성 특발성 두드러기 환자에서 Cyclosporine의 치료 효과와 안전성 및 장기 추적 관찰 결과", 대한피부과학회지, 47(7), pp.759~764 (2009), 대한피부과학회
- 허식, "The Efficacy and Safety of Long-term Oral Cyclosporine Treatment for Patients with Atopic Dermatitis", Annals of Dermatology, 22(1), pp.9~15 (2010), 대한피부과학회
- 박현철, "피부질환 치료에서의 경구 사이클로스포린의 부작용에 대한 연구", 대한피부과학회지, 51(12), pp.960~969 (2013), 대한피부과학회
- Menter A, "Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents", J Am Acad Dermatol, 61, pp.451~485 (2009)[DOI]